<DOC>
	<DOCNO>NCT01039740</DOCNO>
	<brief_summary>The purpose study determine whether pharmacogenetic study predict Mirtazapine responsiveness advance appearance drug effect 4-6 week administration Mirtazapine .</brief_summary>
	<brief_title>Pharmacogenetic Study Mirtazapine Response Depressed Patients</brief_title>
	<detailed_description>The purpose study 1. determine whether genomic difference drug responder nonresponders predict response Mirtazapine 2. construct prediction model Mirtazapine treatment depress patient order aid select genetically matching drug .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>1 . Eligible patient enrol clinical trial program hte Samsung Medical Center Geropsychiatry Affective Disorder Clinics ( Seoul , Korea ) . They receive semistructured diagnostic interview , Samsung Psychiatric Evaluation Schedule . The affective disorder section Samsung Psychiatric Evaluation Schedule use Korean version structure clinical interview diagnostic statistical manual mental disorder , Fourth edition . 2. interview one patient 's family member objective diagnosis final diagnosis decision agreement two psychiatric physician 1. receive psychotropic medication within 2 week study fluoxetine within 4 week 2. potential study participant pregnancy , significant medical condition , abnormal laboratory baseline value , unstable psychiatric feature ( eg.suicidal ) , history alcohol drug dependence , seizure , head trauma loss consciousness , neurological illness , concomitant Axis I psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pharmacogenomics</keyword>
	<keyword>Prediction Mirtazapine response</keyword>
	<keyword>Depressed patient</keyword>
	<keyword>Mirtazapine response</keyword>
	<keyword>Adverse event</keyword>
</DOC>